Creso Pharma’s flagship cannaQIX® exceeds milestone of 2.5 million lozenges sold
Finfeed
Archived
Jan 28, 2020
Creso Pharma Limited (ASX:CPH, FRA:1X8) has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The company has already delivered positive news flow throughout January resulting in its share price increasing by more than 70% from about 11 cents at the start of the month to a high of 19 cents.